5 Stocks To Buy For Long Term: Brokerage recommends strong-fundamental picks with up to 41% upside — See list

ITC remains one of India’s most diversified consumer conglomerates, with cigarettes continuing to anchor cash flows alongside steady growth in FMCG foods, personal care, packaging and agri-business. Sharekhan expects margin stability and improved performance in non-cigarette FMCG segments to support earnings visibility. The brokerage has reiterated a Buy call with a target price of Rs 505, suggesting a 27 per cent upside from the current price of Rs 399. The stock is down 13 per cent in 2025, with a 52-week range of Rs 391 to Rs 471.

Samhi Hotels operates a portfolio of branded hotels across major Indian cities in partnership with global chains such as Marriott. Sharekhan expects a continued recovery in the hospitality sector, supported by higher occupancy levels and improving revenue per available room (RevPAR). The brokerage sees strong operating leverage as demand normalises. Samhi Hotels has been rated Buy with a target price of Rs 246, indicating a 41 per cent upside from the current price of Rs 175. The stock is down 15 per cent in 2025 so far, with a 52-week high of Rs 255 and a low of Rs 120.

Divis Laboratories is among the world’s leading manufacturers of active pharmaceutical ingredients (APIs) and intermediates, with a strong presence in both generic APIs and high-margin custom synthesis for global pharma majors. Sharekhan believes the company’s robust R&D capabilities, clean regulatory track record and growing contribution from custom synthesis make it a premium pharma play. The brokerage has maintained a Buy rating on the stock with a target price of Rs 7,375, implying a 17 per cent upside from the current market price of Rs 6,293. The stock has delivered a 5 per cent return in 2025 so far, with a 52-week high of Rs 7,077 and a low of Rs 4,941.

Zydus Wellness is well positioned to benefit from the growing shift towards health, nutrition and wellness-focused consumer products. Its portfolio includes well-known brands such as Sugar Free, Glucon-D, Complan and Nycil. Sharekhan expects new launches and rising health awareness to drive steady growth. The brokerage has assigned a Buy rating with a target price of Rs 552, implying a 30 per cent upside from the current market price of Rs 426. The stock has gained 8 per cent in 2025, with a 52-week high of Rs 530 and a low of Rs 298.

Varun Beverages, PepsiCo’s largest franchise bottler, continues to benefit from rising consumption of packaged beverages across India and select international markets. Sharekhan believes volume growth, deeper distribution and expansion in juices and water categories will support long-term earnings growth. The brokerage has assigned a Buy rating with a target price of Rs 579, offering a 23 per cent upside from the current market price of Rs 470. The stock has declined 28 per cent in 2025, while its 52-week high and low stand at Rs 664 and Rs 419, respectively.

The views, suggestions and recommendations expressed in this article are solely those of investment experts. Zee Business advises readers to consult their financial advisers before taking any investment decision.